FOLLOWUS
Effects of Adjuvant Chinese Patent Medicine Therapy on Prevention of Variceal Rebleeding: A Retrospective Cohort Study
- Chinese Journal of Integrative Medicine Vol. 27, Issue 8, Pages: 589-596(2021)
- Affiliations：
1.Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing(100015), China
2.Department of Gastroenterology, Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing(100029), China
3.Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing(100700), China
- Author bio：
Dr. WANG Xian-bo, E-mail:wangxb@ccmu.edu.cn
- Funds：
DOI：10.1007/s11655-020-3272-7
CLC：Published：01 August 2021，
Published Online：01 September 2020，
Accepted：20 May 2020
Scan for full text
Qun ZHANG, Yu-xin LI, Yao LIU, et al. Effects of Adjuvant Chinese Patent Medicine Therapy on Prevention of Variceal Rebleeding: A Retrospective Cohort Study. [J]. Chinese Journal of Integrative Medicine 27(8):589-596(2021)
Qun ZHANG, Yu-xin LI, Yao LIU, et al. Effects of Adjuvant Chinese Patent Medicine Therapy on Prevention of Variceal Rebleeding: A Retrospective Cohort Study. [J]. Chinese Journal of Integrative Medicine 27(8):589-596(2021) DOI： 10.1007/s11655-020-3272-7.
摘要
Abstract
Objective:
2
To assess whether adjuvant Chinese patent medicines (CPMs) to standard treatment could reduce recurrent bleeding after variceal bleeding in cirrhotic patients.
Methods:
2
This study retrospectively collected 555 consecutive patients who recovered from variceal bleeding. A population-based cohort study was established depending on if adjuvant CPMs were administered to prevent rebleeding. A total of 139 patients who had taken ≥28 cumulative defined daily doses (cDDDs) of CPMs were included in the CPMs cohort
and 416 patients who used <28 cDDDs of CPMs were enrolled in the non-CPMs cohort. On evaluation of rebleeding incidence
1: 2 propensity score matched was used to estimate for reducing bias. Patients were followed for at least 12 months. The end-point of this study was clinically significant esophagogastric variceal rebleeding.
Results:
2
Following multivariate analysis
CPMs therapy was an independent factor for variceal rebleeding [adjusted hazard ratio (AHR)=0.657; 95% confidence interval=0.497–0.868;
P
=0.003]. After the 1:2 propensity score matching
a significant reduction (23.5%) in the incidence of variceal rebleeding in patients was observed
from 58.3% in the non-CPMs cohort to 44.6% in the CPMs cohort (modified log-rank test
P
=0.002) within a year. The AHRs for rebleeding were 0.928
0.553
and 0.105
for 28–90 cDDDs
91–180 cDDDs
and
>
180 cDDDs of CPMs
respectively. The median rebleeding interval in the CPMs cohort was significantly larger compared with the non-CPMs cohort (113.5 vs. 93.0 days;
P
=0.008).
Conclusion:
2
Adjuvant CPMs to standard therapy can significantly reduce the incidence of variceal rebleeding and delay the time to rebleeding.
关键词
Keywords
adjuvant therapyChinese patent medicinevariceal bleedingvariceal rebleeding
references
Holster IL, Tjwa ET, Moelker A, Wils A, Hansen BE, Vermeijden JR, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology 2016;63:581-589.
Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823-832.
Mehta G, Abraldes JG, Bosch J. Developments and controversies in the management of oesophageal and gastric varices. Gut 2010;59:701-705.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.Hepatology 2017;65:310-335.
Thomas AS, Estep J, Victor DW. Transjugular intrahepatic portosystemic shunt for refractory variceal bleeding in a patient with a left ventricular assist device. ACG Case Rep J 2018;5:e11.
Deltenre P, Trepo E, Rudler M, Monescillo A, Fraga M, Denys A, et al. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials.Eur J Gastroenterol Hepatol 2015;27:e1-e9.
de Franchis R. Expanding consensus in portal hypertension:report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-752.
Cat TB, Liu-DeRyke X. Medical management of variceal hemorrhage. Crit Care Nurs Clin North Am 2010;22:381-393.
Cheung J, Wong W, Zandieh I, Leung Y, Lee SS, Ramji A, et al. Acute management and secondary prophylaxis of esophageal variceal bleeding: a Western Canadian survey.Can J Gastroenterol 2006;20:531-534.
Zhao CQ, Zhou Y, Ping J, Xu LM. Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities. J Integr Med 2014;12:401-408.
Cohen MR. Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in hepatitis C virus. Clin Liver Dis 2001;5:461-478, Ⅶ.
National Health Commission of the People's Republic of China. The National essential drugs list of China (2018 edition). Beijing: People's Medical Publishing House, 2018.
Zhan T, Wei X, Chen ZQ, Wang DS, Dai XP. A systematic review of RCTs and quasi-RCTs on traditional Chinese patent medicines for treatment of chronic hepatitis B. J Tradit Chin Med 2011;31:288-296.
Liu P. Fuzheng Huayu Capsule in the treatment of liver fibrosis: clinical evidence and mechanism of action. Chin J Integr Med 2012;18:398-400.
Liu C, Jiang CM, Liu CH, Liu P, Hu YY. Effect of Fuzheng Huayu Decoction on vascular endothelial growth factor secretion in hepatic stellate cells. Hepatobil Pancreat Dis Int 2002;1:207-210.
Jiang YF, Ma J, He B, Li NP, Tang W, Gong GZ. The therapeutic effect of Anluohuaxian Capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology. Chin J Hepatol (Chin)2012;20:344-347.
Wu G, He HY, Li Y, Chen W. Clinical effect of combination therapy with Fufang Biejia Ruangan Tablet and entecavir in patients with hepatitis B virus-related cirrhosis. Chin J Hepatol (Chin) 2014;22:604-608.
Gu J, Zhang Q, Xue D, Cai H, Xu L. A randomized controlled study of Fuzheng Huayu Capsule for prevention of esophageal variceal bleeding in patients with liver cirrhosis.Evid Based Complement Alternat Med 2013;2013:534960.
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medicial, Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the prevention and treatment of esophageal and gastric varices bleeding in cirrhotic portal hypertension. Chin J Intern Med (Chin) 2016;55:57-72.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460.
Song Y, Zhao J, Wang S, Huang H, Hong J, Zuo J, et al.The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies. Medicine (Baltimore) 2019;98:e15732.
WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Oslo, Norway: ATC/DDD Index 2012. Available from https://www.whocc.no/atc_ddd_index/https://www.whocc.no/atc_ddd_index/. [Accessed on April 14, 2014].
Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013;62:131-137.
Kumar A, Jha SK, Sharma P, Dubey S, Tyagi P, Sharma BC, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009;137:892-901.
Funakoshi N, Segalas-Largey F, Duny Y, Oberti F, Valats JC, Bismuth M, et al. Benefit of combination beta-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 2010;16:5982-5992.
Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006;10:459-479, Ⅶ-Ⅷ.
Lei X, Chen J, Liu CX, Lin J, Lou J, Shang HC. Status and thoughts of Chinese patent medicines seeking approval in the US market. Chin J Integr Med 2014;20:403-408.
Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, et al.Multicenter clinical study on Fuzhenghuayu Capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005;11:2892-2899.
Song YN, Sun JJ, Lu YY, Xu LM, Gao YQ, Zhang W, et al. Therapeutic efficacy of Fuzheng-huayu Tablet based traditional Chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:709305.
Zhou T, Yan XC, Chen Q, Tao YY, Hu YY, Liu P, et al.Effects of Chinese herbal medicine Fuzheng Huayu Recipe and its components against hepatocyte apoptosis in mice with hepatic injury. J Intergr Med (Chin) 2011;9:57-63.
Gong QM, Xiao JC, Zhou XQ. The clinical study of hepatocirrhosis therapy by using of Fufang Biejia Ruangan Tablet. J Clin Hepatol (Chin) 2006;22:196-198.
Yang FR, Fang BW, Lou JS. Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro. World J Gastroenterol 2013;19:5326-5333.
Huang J, Huang H, Jiao Y, Ai G, Huang T, Li L, et al. Effect of Anluohuaxian Tablet combined with gamma-IFN on schistosomal liver fibrosis. J Huazhong Univ Sci Technol Med Sci (Chin) 2009;29:53-58.
Liu P, Liu C, Xu LM, Hu YY, Xue HM, Liu CH, et al. Effects of Fuzheng Huayu 319 Recipe on liver fibrosis in chronic hepatitis B. World J Gastroenterol 1998;4:348-353.
Liu X, Li M, Wang X, Dang Z, Yu L, Wang X, et al. Effects of adjuvant traditional Chinese medicine therapy on longterm survival in patients with hepatocellular carcinoma.Phytomedicine 2019;62:152930.
Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. Liver Intern 2017;37 Suppl 1:104-115.
0
Views
0
Downloads
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
